Among the most promising tools of cancer therapy, engineered immune cells known as chimeric antigen-receptor (CAR) T cells ...

In 2024, Professor Sebastian Kobold's research group at LMU University Hospital had already shown that the metabolite ...

Carfilzomib prevented BCMA degradation, increased target density, and improved CAR T susceptibility by ~26%–28% in vitro, while enhancing xenograft antitumor activity without worsening T-cell ...

In a phase 1 study, anti-CD7 chimeric antigen receptor (CAR) T cells induced complete remission in children and adults with relapsed or refractory T-cell acute lymphoblastic leukemia (ALL), with 82% ...

In the rapidly moving field, questions remain regarding long-term safety, durability of remission, and the FDA’s approach to ...

A method called "in vivo CAR-T (in vivo CAR-T·intra-body CAR-T)" that directly alters immune cells within the body with a single injection is recently changing the landscape of the cancer treatment ...

CAR T-cell therapy, which transforms patients’ own immune cells into cancer-fighting warriors, has revolutionized how physicians treat cancer, especially blood cancers. “These patients can be cured ...

CAR T-cell therapy was first developed as a lymphoma treatment but has recently been applied to autoimmune diseases, primarily lupus, systemic sclerosis, and myositis. Up to this point, ulcerative ...

Colleen Mabasa, a patient with multiple myeloma, sat down with CURE for an interview to discuss how she pursued chimeric antigen receptor (CAR)-T cell therapy, navigated insurance and logistical ...

RNA CAR T therapy Descartes‑08 targets BCMA‑positive plasma cells and delivers year‑long symptom relief in myasthenia gravis after a brief course, signaling a new era of durable treatment.

Jefferson Health oncologist Jennifer Johnson had exhausted all the standard treatment options for her 49-year-old patient ...